Should I buy or sell Larimar Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks .

What is Larimar Therapeutics' stock price target for 2024?

6 analysts have issued 12-month target prices for Larimar Therapeutics' shares. Their LRMR share price targets range from $10.00 to $25.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 192.7% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts .

How have LRMR shares performed in 2024?

Larimar Therapeutics' stock was trading at $4.55 at the beginning of the year. Since then, LRMR stock has increased by 38.9% and is now trading at $6.32. View the best growth stocks for 2024 here .

Are investors shorting Larimar Therapeutics?

Larimar Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,190,000 shares, an increase of 95.7% from the March 15th total of 1,630,000 shares. Based on an average daily trading volume, of 583,700 shares, the short-interest ratio is currently 5.5 days. View Larimar Therapeutics' Short Interest .

When is Larimar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LRMR earnings forecast .

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.05.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:LRMR

Larimar Therapeutics (LRMR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free LRMR Stock Alerts

$6.64

+0.26 (+4.08%)

(As of 01:26 PM ET)

Compare

Today's Range: $6.18
▼
$6.66
50-Day Range: $6.38
▼
$13.28
52-Week Range: $2.18
▼
$13.68

Volume: 213,471 shs
Average Volume: 566,131 shs
Market Capitalization: $423.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.50

Get Larimar Therapeutics alerts:

Larimar Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 192.7% Upside
$18.50 Price Target
Short Interest: Bearish
5.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$37.52 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.24) to ($2.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

388th out of 918 stocks

Pharmaceutical Preparations Industry

173rd out of 423 stocks

4.5

Analyst's Opinion

Consensus Rating
Larimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Larimar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.00% of the outstanding shares of Larimar Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Larimar Therapeutics has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Larimar Therapeutics has recently increased by 95.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Larimar Therapeutics does not currently pay a dividend.
Dividend Growth
Larimar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LRMR.

2.7

News and Social Media Coverage

News Sentiment
Larimar Therapeutics has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 4 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -85% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,521,993.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Larimar Therapeutics is held by insiders.
Percentage Held by Institutions
91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.24) to ($2.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Larimar Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Larimar Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Larimar Therapeutics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Larimar Therapeutics Stock (NASDAQ:LRMR)

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

LRMR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LRMR Stock News Headlines

April 12, 2024 | americanbankingnews.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 95.7% in March

March 18, 2024 | msn.com

5 Stocks that Analysts Love in March 2024

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 16, 2024 | finance.yahoo.com

LRMR Apr 2024 10.000 call

March 16, 2024 | markets.businessinsider.com

Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp

March 14, 2024 | investorplace.com

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023

March 14, 2024 | sfgate.com

Larimar: Q4 Earnings Snapshot

March 14, 2024 | benzinga.com

Recap: Larimar Therapeutics Q4 Earnings

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2024 | finance.yahoo.com

Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results

March 14, 2024 | globenewswire.com

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

March 12, 2024 | markets.businessinsider.com

Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia

March 12, 2024 | msn.com

3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts

March 12, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)

March 11, 2024 | finance.yahoo.com

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

March 11, 2024 | globenewswire.com

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

March 11, 2024 | msn.com

Larimar Therapeutics to Present at Global Biopharma Conference in Miami

March 6, 2024 | globenewswire.com

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

March 3, 2024 | bizjournals.com

Local life sciences companies reeled in more than $750M in stock sales in first two months of 2024

February 23, 2024 | finance.yahoo.com

LRMR Mar 2024 17.500 call

February 23, 2024 | finance.yahoo.com

LRMR Apr 2024 10.000 put

February 22, 2024 | finance.yahoo.com

LRMR Mar 2024 25.000 call

February 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia Treatment

February 19, 2024 | msn.com

Insider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous Purchase

February 19, 2024 | finance.yahoo.com

LRMR Mar 2024 15.000 put

February 18, 2024 | msn.com

Larimar Therapeutics Raises $172.5 Million in Public Offering to Propel Rare Disease Research

February 16, 2024 | finance.yahoo.com

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

See More Headlines

Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LRMR
CUSIP: N/A
CIK: 1374690
Web: larimartx.com
Phone: (844) 511-9056
Fax: N/A
Employees: 42
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.50
High Stock Price Target: $25.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +192.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.83%
Return on Assets: -34.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.49
Quick Ratio: 9.49

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.86 per share
Price / Book: 3.40

Miscellaneous

Outstanding Shares: 63,800,000
Free Float: 61,057,000
Market Cap: $403.22 million
Optionable: Optionable
Beta: 0.93

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Carole S. Ben-Maimon M.D. (Age 65)
CEO, President & Director
Comp: $845.63k
Mr. Michael Celano CPA (Age 65)
Secretary & CFO
Comp: $562.62k
Mr. John Berman
Vice President of Finance & Administration
Ms. Jennifer Spokes Johansson
Vice President of Legal & Compliance
Dr. Russell G. Clayton Sr. (Age 63)
D.O, Chief Medical Officer
Dr. Gopi Shankar M.B.A. (Age 53)
Ph.D., Chief Development Officer
Mr. Francis Michael Conway CPA
VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LRMR Stock Analysis - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares.
View LRMR analyst ratings or view top-rated stocks.
What is Larimar Therapeutics' stock price target for 2024?: 6 analysts have issued 12-month target prices for Larimar Therapeutics' shares. Their LRMR share price targets range from $10.00 to $25.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 192.7% from the stock's current price.
View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts.
How have LRMR shares performed in 2024?: Larimar Therapeutics' stock was trading at $4.55 at the beginning of the year. Since then, LRMR stock has increased by 38.9% and is now trading at $6.32.
View the best growth stocks for 2024 here.
Are investors shorting Larimar Therapeutics?: Larimar Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,190,000 shares, an increase of 95.7% from the March 15th total of 1,630,000 shares. Based on an average daily trading volume, of 583,700 shares, the short-interest ratio is currently 5.5 days.
View Larimar Therapeutics' Short Interest.

When is Larimar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LRMR earnings forecast.
How were Larimar Therapeutics' earnings last quarter?: Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.05.
How do I buy shares of Larimar Therapeutics?: Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LRMR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Larimar Therapeutics (LRMR) Stock Price, News & Analysis

Larimar Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Larimar Therapeutics Stock (NASDAQ:LRMR)

LRMR Stock Price History

LRMR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LRMR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™